Video wird geladen...

Video konnte nicht geladen werden

Zur Startseite

For anyone that has cancer this is important information that Dr. Peter McCullough is discussing. A recent observational report looked at 197 cancer patients prescribed compounded ivermectin (25 mg) plus mebendazole (250 mg). After six months, 122 patients completed follow-up surveys. Here’s what those surveys showed: 84.4% reported clinical...

DawnsMission's profile picture

Dr. Dawn Michael

228,088 subscribers

25,400 Aufrufe • vor 28 Tagen •via X (Twitter)

LIVE

Anya Rossi• Live Now

Private livecam show

24 Kommentare

Profilbild von Dr. Dawn Michael
Dr. Dawn Michaelvor 28 Tagen

Since chemo and radiation destroy the body, I would think more people would want to try medicine that doesn’t destroy the body and actually works to cure the cancer.

Profilbild von Dr. Dawn Michael
Dr. Dawn Michaelvor 27 Tagen

It is very important to get the medication from a reliable source.

Profilbild von Farm Girl Carrie™️👩‍🌾
Farm Girl Carrie™️👩‍🌾vor 28 Tagen

This is promising news.

Profilbild von Dr. Dawn Michael
Dr. Dawn Michaelvor 28 Tagen

It really is!

Profilbild von Guy Placencioguy in exile
Guy Placencioguy in exilevor 27 Tagen

😡 where was this information when my daughter was dying of cancer 23 years ago and no other options to turn to for treatment other than chemo therapy and radiation I was left helpless and trying to fight this for her

Profilbild von Tom Hughes
Tom Hughesvor 28 Tagen

SOME PEOPLE REFUSE TO LISTEN. THEY EAT THEIR OREO COOKIES OR WHATEVER. THEY KNOW SUGAR IS A NO NO DURING CANCER TREATMENT. WTF DON'T ONCOLOGISTS TELL THEIR PATIENCE ?? MSK TOLD ME I COULD EAT ANYTHING I WANTED. I SAID CAKE , YES ANYTHING. IMBECILES

Profilbild von Parody Queen 🇺🇸
Parody Queen 🇺🇸vor 27 Tagen

@CardioFixer God heals today

Profilbild von Sunnydays4071
Sunnydays4071vor 27 Tagen

Giving the dosage is helpful. But is this once a day? How long for? Is it only helpful for some types of cancers? Is the protocol worth doing if cancer is a possibility eg how to know with no biopsy? I am yet to find a protocol I could actually follow, should I need to.

Profilbild von Little Big Man
Little Big Manvor 27 Tagen

@FarmGirlCarrie Why did only 122 of the 197 patients receive a follow up?

Profilbild von Mijne Duifhuis
Mijne Duifhuisvor 27 Tagen

❤️❤️❤️

Profilbild von #LiveLikeJob
#LiveLikeJobvor 28 Tagen

This is great news but unless someone puts money into a controlled study, self-reporting is open to every kind of scrutiny.

Profilbild von Baron
Baronvor 27 Tagen

Fenbendazole works because research shows cancer has the same proliferation and defence system as parasites. Countries that have deworming programmes have 50% less cancers. BigPharma doesn't want you to know this.

Profilbild von Connor Bakers
Connor Bakersvor 21 Tagen

I have been on ivermectin, following @Dr_NancyDavid protocol for liver cancer. I got her complete protocol pack which includes ivermectin, mebendazole, dmso and certain supplements. The cancer has stopped progressing few months ago and my recent scans show that i am cancer free.

Profilbild von NoShtickJewishChick
NoShtickJewishChickvor 27 Tagen

Did it list the types of cancers or is this just generalized?

Profilbild von ABos
ABosvor 27 Tagen

Is there a protocol for post cancer surgery. My wife is 100% clear but we are looking for an alternative to the hormore therapy he doctor is recommending. Thank you

Profilbild von Chris Tew
Chris Tewvor 27 Tagen

I started taking ivermectin, fenbendazole, and mebendazole a couple of years ago as I was completing treatments for multiple myeloma. I believe these drugs have helped keep my cancer at bay for two years.

Profilbild von Mike luers
Mike luersvor 27 Tagen

Great , tear down that trillion dollar industry

Profilbild von jean paul
jean paulvor 27 Tagen

Vu ce résultat demandons une étude en France avec des malades volontaires ,pour voir si ce résultat est confirmé ou pas ; Sous contrôle médical par des médecins volontaires ,avec accord du conseil de l'ordre et pris en charge par la sécu, pour faire avancer la médecine

Profilbild von Santana Nava
Santana Navavor 21 Tagen

Congratulations to all cancer survivors who reversed their cancers through the Ivermectin protocol. I'm currently in complete remission and I'm grateful to @DrS_Washburn for the eye-opener and for incorporating these meds during my stage IV cervical cancer treatment.

Profilbild von Loustaunau Michelle
Loustaunau Michellevor 27 Tagen

Alors peut etre que ces patients sont guerir grace a la chimio et autre traitement conventionnel et pas grace a l ivermectine et au fenbendazole.

Profilbild von Coming in Hot
Coming in Hotvor 27 Tagen

#USA

Profilbild von Chris Tew
Chris Tewvor 27 Tagen

I take a combo of three of these antiparasitic drugs. I believe they have kept my multiple myeloma cancer at bay for two years. Yes I did lots of other treatments too before starting these three drugs.

Profilbild von Fenbendazole Info
Fenbendazole Infovor 26 Tagen

These numbers deserve serious attention. Big Pharma has little financial incentive to champion cheap, repurposed drugs when patented treatments are far more profitable. Follow the data, not the profit margins.

Profilbild von Tom Hughes
Tom Hughesvor 28 Tagen

HAVE YOU HEARD OF EBOO ??

Ähnliche Videos

🚨NEARLY HALF OF CANCER PATIENTS TAKING IVERMECTIN + MEBENDAZOLE REPORTED CANCER DISAPPEARANCE OR TUMOR REGRESSION AFTER 6 MONTHS 84.4% EXPERIENCED CLINICAL BENEFIT 32.8% REPORTED NO EVIDENCE OF DISEASE 15.6% REPORTED TUMOR REGRESSION 36.1% REPORTED STABLE DISEASE Our study represents the largest and most compelling clinical signal to date supporting antiparasitic therapy in cancer.
1:34

🚨NEARLY HALF OF CANCER PATIENTS TAKING IVERMECTIN + MEBENDAZOLE REPORTED CANCER DISAPPEARANCE OR TUMOR REGRESSION AFTER 6 MONTHS 84.4% EXPERIENCED CLINICAL BENEFIT 32.8% REPORTED NO EVIDENCE OF DISEASE 15.6% REPORTED TUMOR REGRESSION 36.1% REPORTED STABLE DISEASE Our study represents the largest and most compelling clinical signal to date supporting antiparasitic therapy in cancer.

Joe Tippens

56,068 Aufrufe • vor 5 Monaten

🚨NEARLY HALF OF CANCER PATIENTS TAKING IVERMECTIN + MEBENDAZOLE REPORTED CANCER DISAPPEARANCE OR TUMOR REGRESSION AFTER 6 MONTHS 84.4% EXPERIENCED CLINICAL BENEFIT 32.8% REPORTED NO EVIDENCE OF DISEASE 15.6% REPORTED TUMOR REGRESSION 36.1% REPORTED STABLE DISEASE Our study represents the largest and most compelling clinical signal to date supporting antiparasitic therapy in cancer. McCullough Foundation The Wellness Company Peter A. McCullough, MD, MPH® Harvey Risch Kelly Victory MD James Thorp MD Dr. Drew Peter Gillooly Foster Coulson
1:34

🚨NEARLY HALF OF CANCER PATIENTS TAKING IVERMECTIN + MEBENDAZOLE REPORTED CANCER DISAPPEARANCE OR TUMOR REGRESSION AFTER 6 MONTHS 84.4% EXPERIENCED CLINICAL BENEFIT 32.8% REPORTED NO EVIDENCE OF DISEASE 15.6% REPORTED TUMOR REGRESSION 36.1% REPORTED STABLE DISEASE Our study represents the largest and most compelling clinical signal to date supporting antiparasitic therapy in cancer. McCullough Foundation The Wellness Company Peter A. McCullough, MD, MPH® Harvey Risch Kelly Victory MD James Thorp MD Dr. Drew Peter Gillooly Foster Coulson

Nicolas Hulscher, MPH

764,601 Aufrufe • vor 5 Monaten

Ivermectin and Mebendazole in Cancer Patients The Clinical Benefit Ratio Complete Response + Partial Response + Stable Disease / Total Patients (CBR) was 84.4% Overall, it is estimated that annual costs of standard chemotherapies average $111,000 per year. Background: Drug repurposing offers a pathway to identify accessible, low-toxicity cancer therapies. Ivermectin and mebendazole have demonstrated multi-target anti-cancer activity. This paper evaluates real-world patient-reported outcomes, safety, and adherence in a cohort of cancer patients utilizing this combination protocol. Methods: Prospective observational cohort of 197 cancer patients, who were prescribed ivermectin and mebendazole off-label through telemedicine (platform by licensed U.S. healthcare providers) Participants received compounded oral capsules containing 25 mg ivermectin and 250 mg mebendazole. Data were collected via voluntary, standardized digital surveys at baseline and at approximately 6-month follow-up. Of the initial cohort (N = 197), baseline characteristics, including cancer type and disease status, were assessed. A total of 122 participants completed the follow-up survey (61.9% response rate) Results: Mean age of 67 years, (52.3% male, 47.7% female). Cancer types included Prostate 27.9% Breast 18.3% Lung 8.6% Colon 5.1% Urologic 4.6% Pancreatic 3.0% Liver 2.5% Gynaecologic 2.5% Hematologic 2.5% Median duration since initial diagnosis, 1.2 years 37.1% experiencing active disease progression. 6-month follow-up Medication adherence, 86.9% Full initial 90-capsule ivermectin-mebendazole prescription. The Clinical Benefit Ratio Complete Response + Partial Response + Stable Disease / Total Patients (CBR) was 84.4% Notably, 48.4% of cohort, strongest positive outcomes: Regression, 15.6% No current evidence of disease (NED), 32.8% Disease stability, 36.1% Disease progression, 15.6% No significant dose-response association was observed for cancer outcomes (p = 0.91), without a clear dose-response gradient for efficacy. Side effects Mild side effects (primarily gastrointestinal), 25.4% (93.6% of those affected continued treatment through minor dose adjustments) Concurrent conventional therapies Chemotherapy, 27.9% Radiation therapy, 21.3% Surgery, 19.7% Adjunctive interventions such as supplement use, 49.2% Dietary modification, 37.7% Conclusions: In this prospective real-world cohort, the combination of ivermectin and mebendazole was associated with high rates of self-reported clinical benefit, with nearly half of participants reporting tumours regression or no current evidence of disease across a heterogeneous population of cancer patients. These findings provide a compelling clinical signal that these well-tolerated, repurposed agents may offer therapeutic benefit. However, observational design, reliance on self-reported outcomes, and potential for selection bias and uncontrolled confounding, these findings should be interpreted as hypothesis-generating. Urgent prospective, randomized, placebo-controlled clinical trials Validate these observations and further define optimal dosing strategies. Mechanism (pharmacodynamics) Ivermectin and mebendazole are antiparasitic agents, demonstrated highly promising anti-cancer activity. Ivermectin Shown to exert over 14 distinct anti-cancer mechanisms across more than 12 cancer types, inhibiting cancer cell proliferation, metastasis, angiogenesis, mitochondrial function. Has demonstrated excellent safety in cancer patients (including those actively undergoing chemotherapy) Ivermectin and mebendazole selectively target cancer stem cells Mebendazole Microtubule disruption, leading to effective cell cycle arrest Potent induction of apoptosis Significant inhibition of tumour growth Inhibition of angiogenesis Disruption of glucose uptake When used together Target non-overlapping pathways, resulting in synergistic tumour regression, cancer stem cell depletion, and reversal of multidrug resistance in multiple in vitro and in vivo models Biodistribution, ivermectin and mebendazole document excellent tissue penetration
24:40

Ivermectin and Mebendazole in Cancer Patients The Clinical Benefit Ratio Complete Response + Partial Response + Stable Disease / Total Patients (CBR) was 84.4% Overall, it is estimated that annual costs of standard chemotherapies average $111,000 per year. Background: Drug repurposing offers a pathway to identify accessible, low-toxicity cancer therapies. Ivermectin and mebendazole have demonstrated multi-target anti-cancer activity. This paper evaluates real-world patient-reported outcomes, safety, and adherence in a cohort of cancer patients utilizing this combination protocol. Methods: Prospective observational cohort of 197 cancer patients, who were prescribed ivermectin and mebendazole off-label through telemedicine (platform by licensed U.S. healthcare providers) Participants received compounded oral capsules containing 25 mg ivermectin and 250 mg mebendazole. Data were collected via voluntary, standardized digital surveys at baseline and at approximately 6-month follow-up. Of the initial cohort (N = 197), baseline characteristics, including cancer type and disease status, were assessed. A total of 122 participants completed the follow-up survey (61.9% response rate) Results: Mean age of 67 years, (52.3% male, 47.7% female). Cancer types included Prostate 27.9% Breast 18.3% Lung 8.6% Colon 5.1% Urologic 4.6% Pancreatic 3.0% Liver 2.5% Gynaecologic 2.5% Hematologic 2.5% Median duration since initial diagnosis, 1.2 years 37.1% experiencing active disease progression. 6-month follow-up Medication adherence, 86.9% Full initial 90-capsule ivermectin-mebendazole prescription. The Clinical Benefit Ratio Complete Response + Partial Response + Stable Disease / Total Patients (CBR) was 84.4% Notably, 48.4% of cohort, strongest positive outcomes: Regression, 15.6% No current evidence of disease (NED), 32.8% Disease stability, 36.1% Disease progression, 15.6% No significant dose-response association was observed for cancer outcomes (p = 0.91), without a clear dose-response gradient for efficacy. Side effects Mild side effects (primarily gastrointestinal), 25.4% (93.6% of those affected continued treatment through minor dose adjustments) Concurrent conventional therapies Chemotherapy, 27.9% Radiation therapy, 21.3% Surgery, 19.7% Adjunctive interventions such as supplement use, 49.2% Dietary modification, 37.7% Conclusions: In this prospective real-world cohort, the combination of ivermectin and mebendazole was associated with high rates of self-reported clinical benefit, with nearly half of participants reporting tumours regression or no current evidence of disease across a heterogeneous population of cancer patients. These findings provide a compelling clinical signal that these well-tolerated, repurposed agents may offer therapeutic benefit. However, observational design, reliance on self-reported outcomes, and potential for selection bias and uncontrolled confounding, these findings should be interpreted as hypothesis-generating. Urgent prospective, randomized, placebo-controlled clinical trials Validate these observations and further define optimal dosing strategies. Mechanism (pharmacodynamics) Ivermectin and mebendazole are antiparasitic agents, demonstrated highly promising anti-cancer activity. Ivermectin Shown to exert over 14 distinct anti-cancer mechanisms across more than 12 cancer types, inhibiting cancer cell proliferation, metastasis, angiogenesis, mitochondrial function. Has demonstrated excellent safety in cancer patients (including those actively undergoing chemotherapy) Ivermectin and mebendazole selectively target cancer stem cells Mebendazole Microtubule disruption, leading to effective cell cycle arrest Potent induction of apoptosis Significant inhibition of tumour growth Inhibition of angiogenesis Disruption of glucose uptake When used together Target non-overlapping pathways, resulting in synergistic tumour regression, cancer stem cell depletion, and reversal of multidrug resistance in multiple in vitro and in vivo models Biodistribution, ivermectin and mebendazole document excellent tissue penetration

Dr. Zakaria MD

10,766 Aufrufe • vor 3 Monaten

🚨 #BREAKING: New PubMed peer reviewed study shows 84% of cancer patients taking ivermectin + mebendazole disappeared, shrunk, or stopped spreading after several months 🔻 The Study and Important Caveats: Researchers followed 197 cancer patients who took a combination of ivermectin and mebendazole (off-label, through a telemedicine service). After 6 months, 122 of them filled out a follow-up survey. Among those 122 people: 84% said their cancer had either completely disappeared, shrunk, or stopped spreading. About 33% reported “no evidence of disease” About 16% reported the tumors got smaller About 36% said the cancer stayed the same (stable) 16% said it got worse Side effects were mostly mild (mainly stomach issues) and most people kept taking the medicine. 🔻 Important caveats: • The results come only from patient surveys — no doctors independently checked scans or medical records. • There was no control group to compare against. • Many patients were also getting regular cancer treatments (chemo, radiation, surgery, etc.) at the same time. • About 38% of the original group didn’t finish the survey. • The journal later issued an official “Expression of Concern” and started an audit because of questions about the data. • The authors say these findings are just a starting point and that proper clinical trials are still needed. 🔻What kinds of cancer were included? Most common Prostate: 55 patients (27.9%) Breast: 36 patients (18.3%) Lung: 17 patients (8.6%) Colon: 10 patients (5.1%) Liver: 5 patients (2.5%) Other cancers (74 patients / 37.6%) Urologic (bladder & kidney): 9 Pancreatic & bile duct: 6 Hematologic (lymphoma): 5 Head, neck & oral: 5 Gynecologic (ovarian & uterine): 5 Thyroid: 4 Brain & neurological: 3 Multiple myeloma: 3 Melanoma (skin & ocular): 3 Sarcoma: 2 Miscellaneous/unspecified: 29 🔻Final Note: The study does not show which cancers benefited the most. All the results (including the 84% figure) are reported only as overall numbers. Clip Study
0:33

🚨 #BREAKING: New PubMed peer reviewed study shows 84% of cancer patients taking ivermectin + mebendazole disappeared, shrunk, or stopped spreading after several months 🔻 The Study and Important Caveats: Researchers followed 197 cancer patients who took a combination of ivermectin and mebendazole (off-label, through a telemedicine service). After 6 months, 122 of them filled out a follow-up survey. Among those 122 people: 84% said their cancer had either completely disappeared, shrunk, or stopped spreading. About 33% reported “no evidence of disease” About 16% reported the tumors got smaller About 36% said the cancer stayed the same (stable) 16% said it got worse Side effects were mostly mild (mainly stomach issues) and most people kept taking the medicine. 🔻 Important caveats: • The results come only from patient surveys — no doctors independently checked scans or medical records. • There was no control group to compare against. • Many patients were also getting regular cancer treatments (chemo, radiation, surgery, etc.) at the same time. • About 38% of the original group didn’t finish the survey. • The journal later issued an official “Expression of Concern” and started an audit because of questions about the data. • The authors say these findings are just a starting point and that proper clinical trials are still needed. 🔻What kinds of cancer were included? Most common Prostate: 55 patients (27.9%) Breast: 36 patients (18.3%) Lung: 17 patients (8.6%) Colon: 10 patients (5.1%) Liver: 5 patients (2.5%) Other cancers (74 patients / 37.6%) Urologic (bladder & kidney): 9 Pancreatic & bile duct: 6 Hematologic (lymphoma): 5 Head, neck & oral: 5 Gynecologic (ovarian & uterine): 5 Thyroid: 4 Brain & neurological: 3 Multiple myeloma: 3 Melanoma (skin & ocular): 3 Sarcoma: 2 Miscellaneous/unspecified: 29 🔻Final Note: The study does not show which cancers benefited the most. All the results (including the 84% figure) are reported only as overall numbers. Clip Study

MJTruthUltra

30,577 Aufrufe • vor 1 Monat

🚨 CANCER PATIENTS — THESE RESULTS DESERVE SERIOUS ATTENTION Dr. Diaz describes what he says is the largest study to date examining ivermectin and mebendazole together in cancer patients. 197 patients. Six months. Used alongside other conventional interventions. According to Dr. Diaz: 84.4% showed clinical benefit. 32.8% showed no evidence of disease. 15.6% experienced tumour regression. Those are extraordinary reported results. If they withstand rigorous scrutiny, the obvious question is: Why wouldn't we investigate this further — urgently? Cancer touches almost every family. Watch this. Listen to the figures. Then ask whether inexpensive, repurposed medicines are receiving the scientific attention they deserve. The Wellness Company Dr. Alejandro Díaz
1:14

🚨 CANCER PATIENTS — THESE RESULTS DESERVE SERIOUS ATTENTION Dr. Diaz describes what he says is the largest study to date examining ivermectin and mebendazole together in cancer patients. 197 patients. Six months. Used alongside other conventional interventions. According to Dr. Diaz: 84.4% showed clinical benefit. 32.8% showed no evidence of disease. 15.6% experienced tumour regression. Those are extraordinary reported results. If they withstand rigorous scrutiny, the obvious question is: Why wouldn't we investigate this further — urgently? Cancer touches almost every family. Watch this. Listen to the figures. Then ask whether inexpensive, repurposed medicines are receiving the scientific attention they deserve. The Wellness Company Dr. Alejandro Díaz

Jim Ferguson

15,180 Aufrufe • vor 1 Monat

🚨IVERMECTIN: FULL DOSAGE SCHEDULE FOR CANCER & PREVENTION Based on Dr. William Makis MD's commonly shared dosing framework Thousands of people reference this ivermectin dosing chart. Below is a simplified breakdown organized by body weight (mg/kg per day). 📌LOW DOSE ≤ 0.5 mg/kg/day Best For: • Cancers in remission • Strong family history or genetic predisposition • Preventive (prophylactic) use Reported Side Effects: • No long-term side effects reported Example: Dr. Tess Lawrie reported a Stage 3 ovarian cancer patient who received chemotherapy plus 12 mg ivermectin daily. After 2 months, the tumor marker CA125 fell from 288 to 22, and the tumor was reported to have disappeared. 📌MEDIUM DOSE 1.0 mg/kg/day Best For: • Starting dose for many cancers including: • Lung cancer • Pancreatic cancer • Renal cell carcinoma • Gastric cancer Reported Side Effects: • No long-term side effects reported Example: Dr. Shankara Chetty reported a 70-year-old prostate cancer patient with a PSA of 89 taking 45 mg daily (along with lactoferrin). After 2 months, PSA reportedly decreased to 10.9. 📌HIGH DOSE 2.0 mg/kg/day Best For: • Aggressive cancers • Leukemia • Pancreatic cancer • Brain cancers Reported Side Effects: • No long-term side effects reported Example: Dr. Allan Landrito reported a Stage 4 gallbladder cancer patient taking 2 mg/kg daily for 14 months, with the cancer reportedly disappearing. 📌VERY HIGH DOSE ≥ 2.5 mg/kg/day Best For: • Extensive metastatic disease • Extremely poor prognosis • Certain aggressive brain cancers Possible Side Effects: • Temporary visual disturbances • Usually, short lived and resolve within days Example: Dr. Shankara Chetty reported using 2.5 mg/kg/day in a patient with no side effects reported. #Ivermectin #MakisMD #Genixmeds
5:47

🚨IVERMECTIN: FULL DOSAGE SCHEDULE FOR CANCER & PREVENTION Based on Dr. William Makis MD's commonly shared dosing framework Thousands of people reference this ivermectin dosing chart. Below is a simplified breakdown organized by body weight (mg/kg per day). 📌LOW DOSE ≤ 0.5 mg/kg/day Best For: • Cancers in remission • Strong family history or genetic predisposition • Preventive (prophylactic) use Reported Side Effects: • No long-term side effects reported Example: Dr. Tess Lawrie reported a Stage 3 ovarian cancer patient who received chemotherapy plus 12 mg ivermectin daily. After 2 months, the tumor marker CA125 fell from 288 to 22, and the tumor was reported to have disappeared. 📌MEDIUM DOSE 1.0 mg/kg/day Best For: • Starting dose for many cancers including: • Lung cancer • Pancreatic cancer • Renal cell carcinoma • Gastric cancer Reported Side Effects: • No long-term side effects reported Example: Dr. Shankara Chetty reported a 70-year-old prostate cancer patient with a PSA of 89 taking 45 mg daily (along with lactoferrin). After 2 months, PSA reportedly decreased to 10.9. 📌HIGH DOSE 2.0 mg/kg/day Best For: • Aggressive cancers • Leukemia • Pancreatic cancer • Brain cancers Reported Side Effects: • No long-term side effects reported Example: Dr. Allan Landrito reported a Stage 4 gallbladder cancer patient taking 2 mg/kg daily for 14 months, with the cancer reportedly disappearing. 📌VERY HIGH DOSE ≥ 2.5 mg/kg/day Best For: • Extensive metastatic disease • Extremely poor prognosis • Certain aggressive brain cancers Possible Side Effects: • Temporary visual disturbances • Usually, short lived and resolve within days Example: Dr. Shankara Chetty reported using 2.5 mg/kg/day in a patient with no side effects reported. #Ivermectin #MakisMD #Genixmeds

GENIX MEDS

31,415 Aufrufe • vor 4 Monaten

100% Cancer Remission Achieved in ALL Patients in Groundbreaking Study Dr. Andrea Cercek, one of the lead researchers, said: “It’s absolutely incredible ... We’ve certainly never seen this before.” All 12 patients experienced complete rectal cancer remission after receiving dostarlimab, a monoclonal antibody. This particular monoclonal antibody achieved 100% cancer remission without chemotherapy, radiation, surgery, or the toxic side effects that come with such therapies. The authors wrote: “All 12 patients (100%; 95% confidence interval) had a clinical complete response, with no evidence of tumor on magnetic resonance imaging ... and no cases of progression or recurrence had been reported during follow-up (range, 6 to 25 months after treatment). No adverse events of grade 3 or higher have been reported.” How does this monoclonal antibody actually work? Dr. Cercek explained that it essentially unlocks the body’s ability to heal itself.
3:28

100% Cancer Remission Achieved in ALL Patients in Groundbreaking Study Dr. Andrea Cercek, one of the lead researchers, said: “It’s absolutely incredible ... We’ve certainly never seen this before.” All 12 patients experienced complete rectal cancer remission after receiving dostarlimab, a monoclonal antibody. This particular monoclonal antibody achieved 100% cancer remission without chemotherapy, radiation, surgery, or the toxic side effects that come with such therapies. The authors wrote: “All 12 patients (100%; 95% confidence interval) had a clinical complete response, with no evidence of tumor on magnetic resonance imaging ... and no cases of progression or recurrence had been reported during follow-up (range, 6 to 25 months after treatment). No adverse events of grade 3 or higher have been reported.” How does this monoclonal antibody actually work? Dr. Cercek explained that it essentially unlocks the body’s ability to heal itself.

The Vigilant Fox 🦊

1,600,645 Aufrufe • vor 2 Jahren

100% Cancer Remission Achieved in ALL Patients of Groundbreaking Study Dr. Andrea Cercek, one of the lead researchers, said: “It’s absolutely incredible ... We’ve certainly never seen this before.” All 12 patients experienced complete rectal cancer remission after receiving dostarlimab, a monoclonal antibody. This particular monoclonal antibody achieved 100% cancer remission without chemotherapy, radiation, surgery, or the toxic side effects that come with such therapies. The authors wrote: “All 12 patients (100%; 95% confidence interval) had a clinical complete response, with no evidence of tumor on magnetic resonance imaging ... and no cases of progression or recurrence had been reported during follow-up (range, 6 to 25 months after treatment). No adverse events of grade 3 or higher have been reported.” How does this monoclonal antibody actually work? Dr. Andrea Cercek explained that it essentially unlocks the body’s ability to heal itself.
3:28

100% Cancer Remission Achieved in ALL Patients of Groundbreaking Study Dr. Andrea Cercek, one of the lead researchers, said: “It’s absolutely incredible ... We’ve certainly never seen this before.” All 12 patients experienced complete rectal cancer remission after receiving dostarlimab, a monoclonal antibody. This particular monoclonal antibody achieved 100% cancer remission without chemotherapy, radiation, surgery, or the toxic side effects that come with such therapies. The authors wrote: “All 12 patients (100%; 95% confidence interval) had a clinical complete response, with no evidence of tumor on magnetic resonance imaging ... and no cases of progression or recurrence had been reported during follow-up (range, 6 to 25 months after treatment). No adverse events of grade 3 or higher have been reported.” How does this monoclonal antibody actually work? Dr. Andrea Cercek explained that it essentially unlocks the body’s ability to heal itself.

The Vigilant Fox 🦊

2,528,335 Aufrufe • vor 2 Jahren

197 Cancer Patients. 84% Reported Clinical Benefit. The Results Are In — And They're Encouraging. Prostate. Breast. Lung. Solid organ cancers across the board — nearly 200 patients tracked for six months on off-label ivermectin and mebendazole. About half saw cancer disappear or regress. A third held stable. The study is conditionally accepted in a peer-reviewed journal. Large-scale randomized trials are the next step. The data says start them now. Join the Fight: Courtesy of The Amber May Show Catch the full episode: #MedicalFreedom
1:17

197 Cancer Patients. 84% Reported Clinical Benefit. The Results Are In — And They're Encouraging. Prostate. Breast. Lung. Solid organ cancers across the board — nearly 200 patients tracked for six months on off-label ivermectin and mebendazole. About half saw cancer disappear or regress. A third held stable. The study is conditionally accepted in a peer-reviewed journal. Large-scale randomized trials are the next step. The data says start them now. Join the Fight: Courtesy of The Amber May Show Catch the full episode: #MedicalFreedom

McCullough Foundation

18,076 Aufrufe • vor 5 Monaten

JAMA Reported That Ivermectin and Mebendazole Use in Cancer Patients Has Skyrocketed. The NCI Has Been Watching. Now They Need to Act. A report from Rockwell and colleagues in JAMA confirms what patient data has been showing for over a year - use of ivermectin and mebendazole among cancer patients surged through 2025. Mel Gibson's appearance on Joe Rogan accelerated it further. The first clinical report shows 84% positive impact - cancers held stable or improved when the combination was added to traditional care. The National Cancer Institute is tracking this. The next step is a large prospective randomized double-blind placebo-controlled trial. The data is there. The patients can't wait. #ivermectin #mebendazole #cancercure
0:54

JAMA Reported That Ivermectin and Mebendazole Use in Cancer Patients Has Skyrocketed. The NCI Has Been Watching. Now They Need to Act. A report from Rockwell and colleagues in JAMA confirms what patient data has been showing for over a year - use of ivermectin and mebendazole among cancer patients surged through 2025. Mel Gibson's appearance on Joe Rogan accelerated it further. The first clinical report shows 84% positive impact - cancers held stable or improved when the combination was added to traditional care. The National Cancer Institute is tracking this. The next step is a large prospective randomized double-blind placebo-controlled trial. The data is there. The patients can't wait. #ivermectin #mebendazole #cancercure

Dr. Alejandro Martínez-Ruiz 🇺🇸🇲🇽

20,223 Aufrufe • vor 2 Monaten

100% Cancer Remission Achieved in ALL Patients in Groundbreaking Study Dr. Andrea Cercek, one of the lead researchers, said: “It’s absolutely incredible ... We’ve certainly never seen this before.” All 12 patients experienced complete rectal cancer remission after receiving dostarlimab, a monoclonal antibody. The authors wrote: “All 12 patients (100%; 95% confidence interval) had a clinical complete response, with no evidence of tumor on magnetic resonance imaging ... and no cases of progression or recurrence had been reported during follow-up (range, 6 to 25 months after treatment). No adverse events of grade 3 or higher have been reported.” How does this monoclonal antibody actually work? Dr. Andrea Cercek explained that it essentially unlocks the body’s ability to heal itself. Watch the breakdown of this study in the comment below.
2:18

100% Cancer Remission Achieved in ALL Patients in Groundbreaking Study Dr. Andrea Cercek, one of the lead researchers, said: “It’s absolutely incredible ... We’ve certainly never seen this before.” All 12 patients experienced complete rectal cancer remission after receiving dostarlimab, a monoclonal antibody. The authors wrote: “All 12 patients (100%; 95% confidence interval) had a clinical complete response, with no evidence of tumor on magnetic resonance imaging ... and no cases of progression or recurrence had been reported during follow-up (range, 6 to 25 months after treatment). No adverse events of grade 3 or higher have been reported.” How does this monoclonal antibody actually work? Dr. Andrea Cercek explained that it essentially unlocks the body’s ability to heal itself. Watch the breakdown of this study in the comment below.

The Vigilant Fox 🦊

1,690,290 Aufrufe • vor 2 Jahren

🚨Dr. William Makis: Ivermectin Dosing for Cancer Explained In one of his recent talks, Dr. William Makis shared what he considers the most important dosing guide for using Ivermectin in cancer. According to Dr. Makis, the starting dose for most cancers is 1 mg per kilogram of body weight per day For example, a person weighing 60 kg would take 60 mg daily, that’s five 12 mg pills or roughly one teaspoon (6 ml) of liquid ivermectin. He mentioned that Ivermectin has shown positive effects in many types of cancer, including: - Breast cancer - Colon cancer - Lung cancer - Pancreatic cancer - Gastric cancer - Renal cell carcinoma - Leukemias He noted that there is very little research on lymphomas, but that doesn’t mean it won’t work, it simply hasn’t been studied much yet. Important points from Dr. Makis: 1) The anti-cancer effect of Ivermectin appears to be dose dependent. 2) Higher doses may offer better results in more aggressive cancers. 3) For very aggressive cancers (such as pancreatic, leukemia, or brain cancers), he suggests considering 2 mg/kg or even up to 2.5 mg/kg per day. Some patients have used these higher doses for many months with only temporary side effects (such as mild visual disturbances that usually resolve within a few days). Real-world examples include a prostate cancer patient whose PSA dropped from 89 to 11 on 45 mg daily, and a terminal gallbladder cancer case that resolved after 14 months on 2 mg/kg. Dr. Makis emphasizes that Ivermectin is a very safe drug with no reported long-term side effects at 1 mg/kg. He recommends starting at this dose and adjusting upwards depending on the individual case and cancer type. He also stresses that people can safely stay on Ivermectin for months as long as there is active disease. If you're researching Ivermectin for cancer protocols, many people are choosing GENIX MEDS for clean, pharmaceutical-grade Ivermectin with straightforward worldwide delivery. #Ivermectindosage #MakisMD #Genixmeds
5:47

🚨Dr. William Makis: Ivermectin Dosing for Cancer Explained In one of his recent talks, Dr. William Makis shared what he considers the most important dosing guide for using Ivermectin in cancer. According to Dr. Makis, the starting dose for most cancers is 1 mg per kilogram of body weight per day For example, a person weighing 60 kg would take 60 mg daily, that’s five 12 mg pills or roughly one teaspoon (6 ml) of liquid ivermectin. He mentioned that Ivermectin has shown positive effects in many types of cancer, including: - Breast cancer - Colon cancer - Lung cancer - Pancreatic cancer - Gastric cancer - Renal cell carcinoma - Leukemias He noted that there is very little research on lymphomas, but that doesn’t mean it won’t work, it simply hasn’t been studied much yet. Important points from Dr. Makis: 1) The anti-cancer effect of Ivermectin appears to be dose dependent. 2) Higher doses may offer better results in more aggressive cancers. 3) For very aggressive cancers (such as pancreatic, leukemia, or brain cancers), he suggests considering 2 mg/kg or even up to 2.5 mg/kg per day. Some patients have used these higher doses for many months with only temporary side effects (such as mild visual disturbances that usually resolve within a few days). Real-world examples include a prostate cancer patient whose PSA dropped from 89 to 11 on 45 mg daily, and a terminal gallbladder cancer case that resolved after 14 months on 2 mg/kg. Dr. Makis emphasizes that Ivermectin is a very safe drug with no reported long-term side effects at 1 mg/kg. He recommends starting at this dose and adjusting upwards depending on the individual case and cancer type. He also stresses that people can safely stay on Ivermectin for months as long as there is active disease. If you're researching Ivermectin for cancer protocols, many people are choosing GENIX MEDS for clean, pharmaceutical-grade Ivermectin with straightforward worldwide delivery. #Ivermectindosage #MakisMD #Genixmeds

GENIX MEDS

20,168 Aufrufe • vor 3 Monaten

JAMA Reported That Ivermectin and Mebendazole Use in Cancer Patients Has Skyrocketed. The NCI Has Been Watching. Now They Need to Act. A report from Rockwell and colleagues in JAMA confirms what patient data has been showing for over a year — use of ivermectin and mebendazole among cancer patients surged through 2025. Mel Gibson's appearance on Joe Rogan accelerated it further. The first clinical report shows 84% positive impact — cancers held stable or improved when the combination was added to traditional care. The National Cancer Institute is tracking this. The next step is a large prospective randomized double-blind placebo-controlled trial. The data is there. The patients can't wait. Join the Fight: Courtesy of Real America's Voice Real America's Voice (RAV), Just The News No Noise John Solomon Amanda Head #MedicalFreedom
0:54

JAMA Reported That Ivermectin and Mebendazole Use in Cancer Patients Has Skyrocketed. The NCI Has Been Watching. Now They Need to Act. A report from Rockwell and colleagues in JAMA confirms what patient data has been showing for over a year — use of ivermectin and mebendazole among cancer patients surged through 2025. Mel Gibson's appearance on Joe Rogan accelerated it further. The first clinical report shows 84% positive impact — cancers held stable or improved when the combination was added to traditional care. The National Cancer Institute is tracking this. The next step is a large prospective randomized double-blind placebo-controlled trial. The data is there. The patients can't wait. Join the Fight: Courtesy of Real America's Voice Real America's Voice (RAV), Just The News No Noise John Solomon Amanda Head #MedicalFreedom

McCullough Foundation

20,331 Aufrufe • vor 3 Monaten

IVERMECTIN: FULL DOSAGE SCHEDULE FOR CANCER & PREVENTION 1000s of people use Dr. William Makis MD’s IVERMECTIN dosing chart. Here’s a clear, categorized breakdown based on body weight (mg/kg per day). LOW DOSE: ≤ 0.5 mg/kg/day **Best for:** - Cancers in remission - Strong family history or genetic predisposition - Prophylaxis (preventive) **Side effects:** No long-term side effects reported. **Example:** Dr. Tess Lawrie reported a Stage 3 ovarian cancer case treated with chemo + 12 mg ivermectin daily. Tumor marker CA125 dropped from 288 to 22 after 2 months and the tumor vanished. MEDIUM DOSE: 1.0 mg/kg/day **Best for:** Starting dose for **most cancers** (lung, pancreatic, renal cell, gastric, etc.). **Side effects:** No long-term side effects reported. **Example:** Dr. Shankara Chetty’s 70-year-old prostate cancer patient (PSA 89) took 45 mg/day (plus lactoferrin). After two months PSA fell to 10.9. HIGH DOSE: 2.0 mg/kg/day **Best for:** Very aggressive cancers (leukemia, pancreatic, brain cancers). **Side effects:** No long-term side effects reported. **Example:** Dr. Allan Landrito’s Stage 4 gallbladder cancer patient took 2 mg/kg daily for 14 months — cancer disappeared. VERY HIGH DOSE: ≥ 2.5 mg/kg/day **Best for:** Extensive metastatic disease, extremely poor prognosis, or certain brain cancers. **Side effects:** Possible short-term & transient visual effects (usually resolve in a few days). **Example:** Dr. Shankara Chetty treated a patient with 2.5 mg/kg/day — no side effects reported. **Quick conversion example (for a 60 kg / 132 lb person):** - Low: ≤30 mg/day - Medium: 60 mg/day (≈5×12 mg tablets or 1 teaspoon liquid) - High: 120 mg/day - Very High: ≥150 mg/day Many anecdotal reports exist of long-term daily use (months to over a year) with no serious toxicity, but individual responses vary. Always work with a knowledgeable clinician, especially if you have pre-existing conditions (e.g., vision issues or glaucoma). This is for educational purposes only. Share to spread awareness — information. Follow for more .
1:00

IVERMECTIN: FULL DOSAGE SCHEDULE FOR CANCER & PREVENTION 1000s of people use Dr. William Makis MD’s IVERMECTIN dosing chart. Here’s a clear, categorized breakdown based on body weight (mg/kg per day). LOW DOSE: ≤ 0.5 mg/kg/day **Best for:** - Cancers in remission - Strong family history or genetic predisposition - Prophylaxis (preventive) **Side effects:** No long-term side effects reported. **Example:** Dr. Tess Lawrie reported a Stage 3 ovarian cancer case treated with chemo + 12 mg ivermectin daily. Tumor marker CA125 dropped from 288 to 22 after 2 months and the tumor vanished. MEDIUM DOSE: 1.0 mg/kg/day **Best for:** Starting dose for **most cancers** (lung, pancreatic, renal cell, gastric, etc.). **Side effects:** No long-term side effects reported. **Example:** Dr. Shankara Chetty’s 70-year-old prostate cancer patient (PSA 89) took 45 mg/day (plus lactoferrin). After two months PSA fell to 10.9. HIGH DOSE: 2.0 mg/kg/day **Best for:** Very aggressive cancers (leukemia, pancreatic, brain cancers). **Side effects:** No long-term side effects reported. **Example:** Dr. Allan Landrito’s Stage 4 gallbladder cancer patient took 2 mg/kg daily for 14 months — cancer disappeared. VERY HIGH DOSE: ≥ 2.5 mg/kg/day **Best for:** Extensive metastatic disease, extremely poor prognosis, or certain brain cancers. **Side effects:** Possible short-term & transient visual effects (usually resolve in a few days). **Example:** Dr. Shankara Chetty treated a patient with 2.5 mg/kg/day — no side effects reported. **Quick conversion example (for a 60 kg / 132 lb person):** - Low: ≤30 mg/day - Medium: 60 mg/day (≈5×12 mg tablets or 1 teaspoon liquid) - High: 120 mg/day - Very High: ≥150 mg/day Many anecdotal reports exist of long-term daily use (months to over a year) with no serious toxicity, but individual responses vary. Always work with a knowledgeable clinician, especially if you have pre-existing conditions (e.g., vision issues or glaucoma). This is for educational purposes only. Share to spread awareness — information. Follow for more .

mcgill_medicines

106,634 Aufrufe • vor 2 Monaten

IVERMECTIN: FULL DOSAGE SCHEDULE FOR CANCER & PREVENTION 1000s of people use Dr. William Makis MD’s IVERMECTIN dosing chart. Here’s a clear, categorized breakdown based on body weight (mg/kg per day). LOW DOSE: ≤ 0.5 mg/kg/day **Best for:** - Cancers in remission - Strong family history or genetic predisposition - Prophylaxis (preventive) **Side effects:** No long-term side effects reported. **Example:** Dr. Tess Lawrie reported a Stage 3 ovarian cancer case treated with chemo + 12 mg ivermectin daily. Tumor marker CA125 dropped from 288 to 22 after 2 months and the tumor vanished. MEDIUM DOSE: 1.0 mg/kg/day **Best for:** Starting dose for **most cancers** (lung, pancreatic, renal cell, gastric, etc.). **Side effects:** No long-term side effects reported. **Example:** Dr. Shankara Chetty’s 70-year-old prostate cancer patient (PSA 89) took 45 mg/day (plus lactoferrin). After two months PSA fell to 10.9. HIGH DOSE: 2.0 mg/kg/day **Best for:** Very aggressive cancers (leukemia, pancreatic, brain cancers). **Side effects:** No long-term side effects reported. **Example:** Dr. Allan Landrito’s Stage 4 gallbladder cancer patient took 2 mg/kg daily for 14 months — cancer disappeared. VERY HIGH DOSE: ≥ 2.5 mg/kg/day **Best for:** Extensive metastatic disease, extremely poor prognosis, or certain brain cancers. **Side effects:** Possible short-term & transient visual effects (usually resolve in a few days). **Example:** Dr. Shankara Chetty treated a patient with 2.5 mg/kg/day — no side effects reported. **Quick conversion example (for a 60 kg / 132 lb person):** - Low: ≤30 mg/day - Medium: 60 mg/day (≈5×12 mg tablets or 1 teaspoon liquid) - High: 120 mg/day - Very High: ≥150 mg/day Many anecdotal reports exist of long-term daily use (months to over a year) with no serious toxicity, but individual responses vary. Always work with a knowledgeable clinician, especially if you have pre-existing conditions (e.g., vision issues or glaucoma). This is for educational purposes only. Share to spread awareness — information is power. 💊
5:47

IVERMECTIN: FULL DOSAGE SCHEDULE FOR CANCER & PREVENTION 1000s of people use Dr. William Makis MD’s IVERMECTIN dosing chart. Here’s a clear, categorized breakdown based on body weight (mg/kg per day). LOW DOSE: ≤ 0.5 mg/kg/day **Best for:** - Cancers in remission - Strong family history or genetic predisposition - Prophylaxis (preventive) **Side effects:** No long-term side effects reported. **Example:** Dr. Tess Lawrie reported a Stage 3 ovarian cancer case treated with chemo + 12 mg ivermectin daily. Tumor marker CA125 dropped from 288 to 22 after 2 months and the tumor vanished. MEDIUM DOSE: 1.0 mg/kg/day **Best for:** Starting dose for **most cancers** (lung, pancreatic, renal cell, gastric, etc.). **Side effects:** No long-term side effects reported. **Example:** Dr. Shankara Chetty’s 70-year-old prostate cancer patient (PSA 89) took 45 mg/day (plus lactoferrin). After two months PSA fell to 10.9. HIGH DOSE: 2.0 mg/kg/day **Best for:** Very aggressive cancers (leukemia, pancreatic, brain cancers). **Side effects:** No long-term side effects reported. **Example:** Dr. Allan Landrito’s Stage 4 gallbladder cancer patient took 2 mg/kg daily for 14 months — cancer disappeared. VERY HIGH DOSE: ≥ 2.5 mg/kg/day **Best for:** Extensive metastatic disease, extremely poor prognosis, or certain brain cancers. **Side effects:** Possible short-term & transient visual effects (usually resolve in a few days). **Example:** Dr. Shankara Chetty treated a patient with 2.5 mg/kg/day — no side effects reported. **Quick conversion example (for a 60 kg / 132 lb person):** - Low: ≤30 mg/day - Medium: 60 mg/day (≈5×12 mg tablets or 1 teaspoon liquid) - High: 120 mg/day - Very High: ≥150 mg/day Many anecdotal reports exist of long-term daily use (months to over a year) with no serious toxicity, but individual responses vary. Always work with a knowledgeable clinician, especially if you have pre-existing conditions (e.g., vision issues or glaucoma). This is for educational purposes only. Share to spread awareness — information is power. 💊

Valerie Anne Smith

972,836 Aufrufe • vor 4 Monaten

IVERMECTIN: FULL DOSAGE SCHEDULE FOR CANCER & PREVENTION 1000s of people use Dr. William Makis MD’s IVERMECTIN dosing chart. Here’s a clear, categorized breakdown based on body weight (mg/kg per day). LOW DOSE: ≤ 0.5 mg/kg/day **Best for:** - Cancers in remission - Strong family history or genetic predisposition - Prophylaxis (preventive) **Side effects:** No long-term side effects reported. **Example:** Dr. Tess Lawrie reported a Stage 3 ovarian cancer case treated with chemo + 12 mg ivermectin daily. Tumor marker CA125 dropped from 288 to 22 after 2 months and the tumor vanished. MEDIUM DOSE: 1.0 mg/kg/day **Best for:** Starting dose for **most cancers** (lung, pancreatic, renal cell, gastric, etc.). **Side effects:** No long-term side effects reported. **Example:** Dr. Shankara Chetty’s 70-year-old prostate cancer patient (PSA 89) took 45 mg/day (plus lactoferrin). After two months PSA fell to 10.9. HIGH DOSE: 2.0 mg/kg/day **Best for:** Very aggressive cancers (leukemia, pancreatic, brain cancers). **Side effects:** No long-term side effects reported. **Example:** Dr. Allan Landrito’s Stage 4 gallbladder cancer patient took 2 mg/kg daily for 14 months — cancer disappeared. VERY HIGH DOSE: ≥ 2.5 mg/kg/day **Best for:** Extensive metastatic disease, extremely poor prognosis, or certain brain cancers. **Side effects:** Possible short-term & transient visual effects (usually resolve in a few days). **Example:** Dr. Shankara Chetty treated a patient with 2.5 mg/kg/day — no side effects reported. **Quick conversion example (for a 60 kg / 132 lb person):** - Low: ≤30 mg/day - Medium: 60 mg/day (≈5×12 mg tablets or 1 teaspoon liquid) - High: 120 mg/day - Very High: ≥150 mg/day Many anecdotal reports exist of long-term daily use (months to over a year) with no serious toxicity, but individual responses vary. Always work with a knowledgeable clinician, especially if you have pre-existing conditions (e.g., vision issues or glaucoma). This is for educational purposes only. Share to spread awareness — information is power. 💊
5:47

IVERMECTIN: FULL DOSAGE SCHEDULE FOR CANCER & PREVENTION 1000s of people use Dr. William Makis MD’s IVERMECTIN dosing chart. Here’s a clear, categorized breakdown based on body weight (mg/kg per day). LOW DOSE: ≤ 0.5 mg/kg/day **Best for:** - Cancers in remission - Strong family history or genetic predisposition - Prophylaxis (preventive) **Side effects:** No long-term side effects reported. **Example:** Dr. Tess Lawrie reported a Stage 3 ovarian cancer case treated with chemo + 12 mg ivermectin daily. Tumor marker CA125 dropped from 288 to 22 after 2 months and the tumor vanished. MEDIUM DOSE: 1.0 mg/kg/day **Best for:** Starting dose for **most cancers** (lung, pancreatic, renal cell, gastric, etc.). **Side effects:** No long-term side effects reported. **Example:** Dr. Shankara Chetty’s 70-year-old prostate cancer patient (PSA 89) took 45 mg/day (plus lactoferrin). After two months PSA fell to 10.9. HIGH DOSE: 2.0 mg/kg/day **Best for:** Very aggressive cancers (leukemia, pancreatic, brain cancers). **Side effects:** No long-term side effects reported. **Example:** Dr. Allan Landrito’s Stage 4 gallbladder cancer patient took 2 mg/kg daily for 14 months — cancer disappeared. VERY HIGH DOSE: ≥ 2.5 mg/kg/day **Best for:** Extensive metastatic disease, extremely poor prognosis, or certain brain cancers. **Side effects:** Possible short-term & transient visual effects (usually resolve in a few days). **Example:** Dr. Shankara Chetty treated a patient with 2.5 mg/kg/day — no side effects reported. **Quick conversion example (for a 60 kg / 132 lb person):** - Low: ≤30 mg/day - Medium: 60 mg/day (≈5×12 mg tablets or 1 teaspoon liquid) - High: 120 mg/day - Very High: ≥150 mg/day Many anecdotal reports exist of long-term daily use (months to over a year) with no serious toxicity, but individual responses vary. Always work with a knowledgeable clinician, especially if you have pre-existing conditions (e.g., vision issues or glaucoma). This is for educational purposes only. Share to spread awareness — information is power. 💊

Joe Tippens

136,707 Aufrufe • vor 3 Monaten

Next onto my conversation with Dr. Ashish Kamat Ashish M. Kamat, MD, MBBS and one of the country's leading bladder cancer experts to hear his clinical decision making process as to how he treats patients with BCG unresponsive high-grade papillary disease when no CIS disease is found. (I said the word 'found' since sometimes once high-grade papillary disease is identified, physicians don't bother to look for CIS since their decision making process for treatment is the same if high-grade papillary alone exists. Worse, only 6% of urologists have the blue-light cystoscopy scope that helps them find CIS disease). Dr. Kamat who participated in the initial guidelines discussion with regard to BCG unresponsive in 2016, gave me an insightful answer as to how he treats patients clinically with high-grade papillary alone. Please listen to his insightful answer, the editor of the seminal textbook entitled, "Bladder Cancer: A Practical Guide". He treats patients with high-grade papillary disease alone no differently than in patients with high-grade papillary and CIS disease. This was not surprising for me to hear since he and many others believe that CIS and papillary are the same disease! The next day I attended the FDA workshop in which his fellow colleagues concurred that CIS and papillary was the same disease and also said that they approached patients with BCG unresponsive high-grade papillary disease in the same way as he shared with me in this interview, taken the day before the FDA workshop. His fellow colleagues and experts at the workshop said that they "struggled" and were compelled to make decisions with no option but to prescribe "off-label" therapies for patients who they see (with papillary disease alone) by writing a prescription for already FDA approved therapies for papillary and CIS disease. So the consensus at this panel completely matched the panel of experts from comprehensive cancer centers across the nation who made up the NCCN and provided category 2A status for Anktiva + BCG for the treatment of BCG unresponsive papillary disease alone. Cancer is a war against time Disclaimer: Anktiva + BCG for the treatment of BCG unresponsive papillary disease is not approved and is awaiting review by the FDA as a supplemental BLA. For more details of ANKTIVA + BCG, please refer to our package insert and important safety information. ANKTIVA is approved by the FDA in combination with BCG for the treatment of adult patients with BCG-unresponsive NMIBC with carcinoma in-situ (CIS), with or without papillary tumors. Important Safety Information U.S. IMPORTANT SAFETY INFORMATION INDICATION AND USAGE: ANKTIVA® is an interleukin-15 (IL-15) receptor agonist indicated with Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. WARNINGS AND PRECAUTIONS: Risk of Metastatic Bladder Cancer with Delayed Cystectomy. Delaying cystectomy can lead to the development of muscle-invasive or metastatic bladder cancer, which can be lethal. If patients with CIS do not have a complete response to treatment after a second induction course of ANKTIVA® with BCG, reconsider cystectomy. DOSAGE AND ADMINISTRATION: For Intravesical Use Only. Do not administer by subcutaneous or intravenous routes. Please see the complete Indication and Important Safety Information and Prescribing Information for ANKTIVA® at
1:14

Next onto my conversation with Dr. Ashish Kamat Ashish M. Kamat, MD, MBBS and one of the country's leading bladder cancer experts to hear his clinical decision making process as to how he treats patients with BCG unresponsive high-grade papillary disease when no CIS disease is found. (I said the word 'found' since sometimes once high-grade papillary disease is identified, physicians don't bother to look for CIS since their decision making process for treatment is the same if high-grade papillary alone exists. Worse, only 6% of urologists have the blue-light cystoscopy scope that helps them find CIS disease). Dr. Kamat who participated in the initial guidelines discussion with regard to BCG unresponsive in 2016, gave me an insightful answer as to how he treats patients clinically with high-grade papillary alone. Please listen to his insightful answer, the editor of the seminal textbook entitled, "Bladder Cancer: A Practical Guide". He treats patients with high-grade papillary disease alone no differently than in patients with high-grade papillary and CIS disease. This was not surprising for me to hear since he and many others believe that CIS and papillary are the same disease! The next day I attended the FDA workshop in which his fellow colleagues concurred that CIS and papillary was the same disease and also said that they approached patients with BCG unresponsive high-grade papillary disease in the same way as he shared with me in this interview, taken the day before the FDA workshop. His fellow colleagues and experts at the workshop said that they "struggled" and were compelled to make decisions with no option but to prescribe "off-label" therapies for patients who they see (with papillary disease alone) by writing a prescription for already FDA approved therapies for papillary and CIS disease. So the consensus at this panel completely matched the panel of experts from comprehensive cancer centers across the nation who made up the NCCN and provided category 2A status for Anktiva + BCG for the treatment of BCG unresponsive papillary disease alone. Cancer is a war against time Disclaimer: Anktiva + BCG for the treatment of BCG unresponsive papillary disease is not approved and is awaiting review by the FDA as a supplemental BLA. For more details of ANKTIVA + BCG, please refer to our package insert and important safety information. ANKTIVA is approved by the FDA in combination with BCG for the treatment of adult patients with BCG-unresponsive NMIBC with carcinoma in-situ (CIS), with or without papillary tumors. Important Safety Information U.S. IMPORTANT SAFETY INFORMATION INDICATION AND USAGE: ANKTIVA® is an interleukin-15 (IL-15) receptor agonist indicated with Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. WARNINGS AND PRECAUTIONS: Risk of Metastatic Bladder Cancer with Delayed Cystectomy. Delaying cystectomy can lead to the development of muscle-invasive or metastatic bladder cancer, which can be lethal. If patients with CIS do not have a complete response to treatment after a second induction course of ANKTIVA® with BCG, reconsider cystectomy. DOSAGE AND ADMINISTRATION: For Intravesical Use Only. Do not administer by subcutaneous or intravenous routes. Please see the complete Indication and Important Safety Information and Prescribing Information for ANKTIVA® at

Dr. Pat Soon-Shiong

21,953 Aufrufe • vor 4 Monaten

🚨 “LOW TO VERY HIGH DOSES.” DR. WILLIAM MAKIS’ IVERMECTIN PROTOCOL FOR PARASITES, CANCER, FAMILY HISTORY & NEUROLOGICAL CONDITIONS Ivermectin is best known as an antiparasitic medicine. But Dr. William Makis discusses a much broader range of potential applications, including Parkinson’s disease, Alzheimer’s disease and cancer-related protocols. The accompanying Ivermectin protocol graphic organizes his reported dosing framework into four tiers. 📋 Ivermectin dosage framework shown in the chart Ivermectin Dosage Guide 🟢 LOW Anti-parasitic: 0.0267 g/kg • 3 days on, 4 days off • Minimum 7 weeks • Supplements: OFF days Cancer remission: 222 mg • 3 days on, 4 days off • Minimum 7 weeks • Supplements: OFF days Family history: 444 mg • 3 days on, 4 days off • Minimum 7 weeks • Supplements: OFF days 🟡 MEDIUM Anti-parasitic / most cancers: 0.0535 g/kg • 6 days on, 1 day off • Until remission • Minimum 3 months Cancer: 444 mg • 6 days on, 1 day off • Until remission • Minimum 3 months 🔵 HIGH Aggressive cancers: 0.1070 g/kg • 6 days on, 1 day off • Until remission Leukemia, pancreatic, brain: 888–1,000 mg split doses • 6 days on, 1 day off • Until remission 🔴 VERY HIGH Terminal, metastatic cancers: 0.1337 g/kg • 6 days on, 1 day off • Short term Cancer: 1,500 mg split doses • 6 days on, 1 day off • Maximum 5 days ⚠️ Do not start any treatment without guidance from a doctor or qualified physician. 🧠 Then comes the neurological angle Makis says the neurological conditions where he has seen what he describes as the most success are: Parkinson’s disease + Alzheimer’s disease 1️⃣ Parkinson’s disease Makis describes cases involving what he calls high-dose Ivermectin, specifically mentioning: 60 mg → 72 mg He reports improvements in: • Movement • Mobility • Symptoms One patient he describes was barely mobile despite maximum standard treatment. After several weeks of high-dose Ivermectin, he says the patient started playing golf again, despite having been unable to play for years. He also says he has seen what he describes as reversal in a number of Parkinson’s patients. 2️⃣ Alzheimer’s disease This is where Makis says the stories became even more striking. He describes families reporting that elderly patients: • Recognized relatives again • Remembered people they had not recognized for years • Started reminiscing • Recalled old memories • Showed improved cognitive ability For these cases, he specifically discusses: 12 mg → 24 mg of Ivermectin He describes these amounts being used for several days in the cases he discusses. One particularly striking account involves a patient who was reportedly taken off hospice after improving. And the family reaction? “My grandma’s back.” Antiparasitic conditions. Cancer remission. Family history. Aggressive cancers. Metastatic cancers. Parkinson’s disease. Alzheimer’s disease. Different conditions. Different reported applications. Different reported dosing approaches. But one medicine: 💊 Ivermectin. 🔥 The breadth of the discussion is hard to ignore From an established antiparasitic medicine to reported applications involving cancer, Parkinson’s and Alzheimer’s, Ivermectin is now part of a much broader research conversation. Different conditions. Different reported experiences. One medicine generating very different questions across medicine. From antiparasitic protocols to reported cancer applications, Parkinson’s and Alzheimer’s cases, this video + protocol chart covers a lot. 🗨️ Which area deserves the most research attention: cancer, Parkinson’s, Alzheimer’s, parasites, or something else? 🔖 SAVE this post so you have Ivermectin dosing framework and the full video discussion handy. 🔄 REPOST to help others discover the broader research and clinical discussions surrounding Ivermectin. 💊 Looking for Ivermectin? Discover available options at RXMEDS.STORE with worldwide delivery. #Ivermectin #CancerResearch #Parkinsons #Alzheimers #Neurology #RepurposedMedicine #MakisMD #RxMeds
3:57

🚨 “LOW TO VERY HIGH DOSES.” DR. WILLIAM MAKIS’ IVERMECTIN PROTOCOL FOR PARASITES, CANCER, FAMILY HISTORY & NEUROLOGICAL CONDITIONS Ivermectin is best known as an antiparasitic medicine. But Dr. William Makis discusses a much broader range of potential applications, including Parkinson’s disease, Alzheimer’s disease and cancer-related protocols. The accompanying Ivermectin protocol graphic organizes his reported dosing framework into four tiers. 📋 Ivermectin dosage framework shown in the chart Ivermectin Dosage Guide 🟢 LOW Anti-parasitic: 0.0267 g/kg • 3 days on, 4 days off • Minimum 7 weeks • Supplements: OFF days Cancer remission: 222 mg • 3 days on, 4 days off • Minimum 7 weeks • Supplements: OFF days Family history: 444 mg • 3 days on, 4 days off • Minimum 7 weeks • Supplements: OFF days 🟡 MEDIUM Anti-parasitic / most cancers: 0.0535 g/kg • 6 days on, 1 day off • Until remission • Minimum 3 months Cancer: 444 mg • 6 days on, 1 day off • Until remission • Minimum 3 months 🔵 HIGH Aggressive cancers: 0.1070 g/kg • 6 days on, 1 day off • Until remission Leukemia, pancreatic, brain: 888–1,000 mg split doses • 6 days on, 1 day off • Until remission 🔴 VERY HIGH Terminal, metastatic cancers: 0.1337 g/kg • 6 days on, 1 day off • Short term Cancer: 1,500 mg split doses • 6 days on, 1 day off • Maximum 5 days ⚠️ Do not start any treatment without guidance from a doctor or qualified physician. 🧠 Then comes the neurological angle Makis says the neurological conditions where he has seen what he describes as the most success are: Parkinson’s disease + Alzheimer’s disease 1️⃣ Parkinson’s disease Makis describes cases involving what he calls high-dose Ivermectin, specifically mentioning: 60 mg → 72 mg He reports improvements in: • Movement • Mobility • Symptoms One patient he describes was barely mobile despite maximum standard treatment. After several weeks of high-dose Ivermectin, he says the patient started playing golf again, despite having been unable to play for years. He also says he has seen what he describes as reversal in a number of Parkinson’s patients. 2️⃣ Alzheimer’s disease This is where Makis says the stories became even more striking. He describes families reporting that elderly patients: • Recognized relatives again • Remembered people they had not recognized for years • Started reminiscing • Recalled old memories • Showed improved cognitive ability For these cases, he specifically discusses: 12 mg → 24 mg of Ivermectin He describes these amounts being used for several days in the cases he discusses. One particularly striking account involves a patient who was reportedly taken off hospice after improving. And the family reaction? “My grandma’s back.” Antiparasitic conditions. Cancer remission. Family history. Aggressive cancers. Metastatic cancers. Parkinson’s disease. Alzheimer’s disease. Different conditions. Different reported applications. Different reported dosing approaches. But one medicine: 💊 Ivermectin. 🔥 The breadth of the discussion is hard to ignore From an established antiparasitic medicine to reported applications involving cancer, Parkinson’s and Alzheimer’s, Ivermectin is now part of a much broader research conversation. Different conditions. Different reported experiences. One medicine generating very different questions across medicine. From antiparasitic protocols to reported cancer applications, Parkinson’s and Alzheimer’s cases, this video + protocol chart covers a lot. 🗨️ Which area deserves the most research attention: cancer, Parkinson’s, Alzheimer’s, parasites, or something else? 🔖 SAVE this post so you have Ivermectin dosing framework and the full video discussion handy. 🔄 REPOST to help others discover the broader research and clinical discussions surrounding Ivermectin. 💊 Looking for Ivermectin? Discover available options at RXMEDS.STORE with worldwide delivery. #Ivermectin #CancerResearch #Parkinsons #Alzheimers #Neurology #RepurposedMedicine #MakisMD #RxMeds

RXMEDS.STORE

14,786 Aufrufe • vor 13 Tagen

The Remarkable Cancer-Fighting Benefits of Ivermectin • “Ivermectin can actually kill cancer stem cells,” which are often resistant to chemotherapy. • “It can also reverse resistance that cancer cells develop to chemotherapy,” making treatments more effective. • “It makes cancer cells susceptible to radiation treatment as well. And so it’s a radiosensitizer.” • Patients are seeing “tumors shrinking down to almost nothing, liver metastases disappearing, [and] brain metastases disappearing.” “There are over 100 papers on the success of ivermectin and cancer,” but much of this research has been ignored because the drug is off-patent, meaning “no one’s going to make money on it.” Dr. Makis has treated over 1,000 patients using combinations of ivermectin, fenbendazole, and other therapies. Many of his patients, told by their doctors that there was “nothing they can do for them,” are now “cancer-free” or have their “cancer under control.” The success stories are undeniable, and the hope is spreading. MakisMD
4:13

The Remarkable Cancer-Fighting Benefits of Ivermectin • “Ivermectin can actually kill cancer stem cells,” which are often resistant to chemotherapy. • “It can also reverse resistance that cancer cells develop to chemotherapy,” making treatments more effective. • “It makes cancer cells susceptible to radiation treatment as well. And so it’s a radiosensitizer.” • Patients are seeing “tumors shrinking down to almost nothing, liver metastases disappearing, [and] brain metastases disappearing.” “There are over 100 papers on the success of ivermectin and cancer,” but much of this research has been ignored because the drug is off-patent, meaning “no one’s going to make money on it.” Dr. Makis has treated over 1,000 patients using combinations of ivermectin, fenbendazole, and other therapies. Many of his patients, told by their doctors that there was “nothing they can do for them,” are now “cancer-free” or have their “cancer under control.” The success stories are undeniable, and the hope is spreading. MakisMD

TheSkyMeds | Cancer & Parasites Explained

5,144,279 Aufrufe • vor 1 Jahr